Form 4: Halozyme Therapeutics Executive Awarded Performance-Based Stock Units

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, received performance-based stock units that vested based on performance ending December 31, 2024, subject to continued service.

Summary

• On February 12, 2025, Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, reported transactions related to performance stock units (PSUs).
• These PSUs were awarded on February 16, 2022, February 16, 2023, and February 23, 2024, with a performance measurement period ending December 31, 2024.
• The transactions represent the determination of the number of stock units that became eligible to vest based on performance during that period.
• The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
• LaBarre acquired 7,262, 4,177, 4,921 and 20,342 performance stock units on February 12, 2025.
• Following these transactions, LaBarre directly owns 20,891, 6,547, 4,921 and 20,342 performance stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of performance stock units suggests the company met certain performance goals, which is a positive indicator. However, the value is contingent on future stock performance.

Positives

• The vesting of performance stock units suggests that Halozyme Therapeutics met certain performance targets.
• The continued service requirement aligns the executive's interests with the long-term success of the company.

Risks

• The value of the stock units is contingent on the future performance of Halozyme Therapeutics' stock.
• The service-based vesting requirement means the executive must remain employed to fully realize the value of the units.

Future Outlook

The executive's compensation is tied to the company's performance and continued service, suggesting an expectation of future value creation.

Industry Context

Performance-based compensation is a common practice in the biotechnology industry to incentivize executives and align their interests with shareholder value.

Comparison to Industry Standards

• Stock options and restricted stock units are standard components of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Performance-based vesting criteria are also common, with metrics tied to clinical trial milestones, regulatory approvals, or revenue targets.
• Companies like Amgen, Gilead, and Regeneron also utilize similar compensation structures to incentivize their executives.

Stakeholder Impact

• Shareholders may view the vesting of performance stock units as a positive sign, indicating that the company is achieving its goals.
• Employees may be motivated by the fact that executive compensation is tied to company performance.

Next Steps

• The executive will continue to hold the vested stock units, subject to the service-based vesting requirement.
• The executive may choose to exercise or sell the stock units in the future, subject to company policies and securities regulations.

Key Dates

Keywords

Performance Stock Units, Halozyme Therapeutics, Executive Compensation, Form 4, LaBarre, Vesting